Emerging preclinical studies revealed diverse immunomodulatory effects of CDK4/6 inhibition, such as an enhanced immune infiltration into the tumor microenvironment, elevated antigen presentation and modulation of the cytokine milieu, supporting antitumor immune response (Ameratunga et al., 2019). Here, CDK4 is linked to neoplasm.